[HTML] cdc.gov

[HTML][HTML] Hospitalization and emergency department encounters for COVID-19 after paxlovid treatment—California, December 2021–May 2022

DE Malden - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment
— California, December 2021–May 2022 | MMWR Skip directly to site content Skip directly to …
被引用次数：68 相关文章

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment-California, December 2021-May 2022.

DE Malden, V Hong, BJ Lewin… - MMWR: Morbidity & …, 2022 - search.ebscohost.com
Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of
SARS-CoV-2 (the virus that causes COVID-19) and has been shown to reduce the risk for …

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment-California, December 2021-May 2022.

DE Malden, V Hong, BJ Lewin… - MMWR. Morbidity and …, 2022 - europepmc.org
Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of
SARS-CoV-2 (the virus that causes COVID-19) and has been shown to reduce the risk for …

Hospitalization and emergency department encounters for COVID-19 after paxlovid treatment-California, December 2021-May 2022.

DE Malden, V Hong, BJ Lewin, BK Ackerson… - 2022 - cabidigitallibrary.org
Recurrence of COVID-19 symptoms and positive SARS-CoV-2 test results have been
reported after completion of Paxlovid oral antiviral treatment for COVID-19, but real world …

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment-California, December 2021-May 2022

DE Malden, V Hong, BJ Lewin… - MMWR. Morbidity …, 2022 - pubmed.ncbi.nlm.nih.gov
Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of
SARS-CoV-2 (the virus that causes COVID-19) and has been shown to reduce the risk for …